Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952406 | 0.85 | PKM (0.43) | MAPTPKMPOLBPTGER4NPSR1 | |
| SCHEMBL3947534 | 0.81 | HCAR3 (0.48) | MAPTPKMPOLBNPSR1HCAR3 | |
| SCHEMBL29384452 | 0.78 | PTGER4 (0.61) | MAPTPKMPOLBPTGER4NPSR1 | |
| SCHEMBL22499572 | 0.78 | PTGER4 (0.61) | MAPTPKMPOLBPTGER4NPSR1 | |
| SCHEMBL3054683 | 0.77 | CA12 (0.55) | KMT2ASMN1; SMN2LMNAALDH1A1CASP3 | |
| SCHEMBL3950211 | 0.77 | CNR2 (0.61) | — | |
| SCHEMBL29384467 | 0.76 | PTGER4 (0.52) | GSTO1MAPTPKMPOLBPTGER4 | |
| SCHEMBL22499591 | 0.76 | PTGER4 (0.52) | GSTO1MAPTPKMPOLBPTGER4 | |
| SCHEMBL22499578 | 0.75 | PTGER4 (0.51) | GSTO1MAPTPKMPOLBPTGER4 | |
| SCHEMBL29383996 | 0.75 | PTGER4 (0.51) | GSTO1MAPTPKMPOLBPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544676-B2 | Sulfamoyl benzamides and methods of their use | ADOLOR CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544676-B2 | Sulfamoyl benzamides and methods of their use | ADOLOR CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544676-B2 | Sulfamoyl benzamides and methods of their use | ADOLOR CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CALIXA THERAPEUTICS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CALIXA THERAPEUTICS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CALIXA THERAPEUTICS, INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CNR2, TRPV1, CNR1 | GSTO1 4548/4885MAPT 3596/4885PKM 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.